TABLE 1.
Clinical characteristics of headache and associated symptoms in healthy volunteers after glibenclamide and placebo (0–14 h observation period).
| Participants | Peak headache (duration of headache) | Headache characteristics | Associated symptoms | Migraine-like attacks (onset) | Treatment (time)/efficacy |
| 1 | |||||
| Glibenclamide-CGRP | None | ||||
| Placebo-CGRP | 140 min (40 min) | Bilat/1/press/− | − / − / − | no | None |
| 2 | |||||
| Glibenclamide-CGRP | 130 min (420 min) | Bilat/3/press/+ | − / − /− | no | None |
| Placebo-CGRP | 150 min (310 min) | Bilat/2/press/− | − / − /− | no | None |
| 3 | |||||
| Glibenclamide-CGRP | 140 min (420 min) | Bilat/2/press+throb/+ | − / − /− | no | Paracetamol 1 g (9 h/yes) |
| Placebo-CGRP | 130 min (440 min) | Bilat/3/press+throb/+ | − / − /− | no | Paracetamol 1 g (7 h/yes) |
| 4 | |||||
| Glibenclamide-CGRP | 140 min (80 min) | Bilat/1/press/− | + / − /− | no | None |
| Placebo-CGRP | 130 min (50 min) | Bilat/1/press+throb/− | + / − /− | no | None |
| 5 | |||||
| Glibenclamide-CGRP | 130 min (250 min) | Bilat/6/throb/+ | +/ − /− | Yes | None |
| Placebo-CGRP | 10 min (90 min) | Bilat/1/throb+ press/+ | −/ − /− | no | None |
| 6 | |||||
| Glibenclamide-CGRP | None | ||||
| Placebo-CGRP | 130 min (30 min) | Bilat/1/throb/− | − / − /− | no | None |
| 7 | |||||
| Glibenclamide-CGRP | none | ||||
| Placebo-CGRP | 180 min (170 min) | unileft/3/press+throb/− | − / + /− | no | None |
| 8 | |||||
| Glibenclamide-CGRP | 540 min (550 min) | Bilat/6/press+throb/− | − / − /+ | no | Paracetamol 1 g (11 h/yes) |
| Placebo-CGRP | 540 min (150 min) | Bilat/4/press+throb/− | − / − /+ | no | None |
| 9 | |||||
| Glibenclamide-CGRP | 130 min (50 min) | Bilat/1/press+throb/− | − / − /− | no | None |
| Placebo-CGRP | 130 min (30 min | Bilat/1/throb/− | − / − /− | no | None |
| 10 | |||||
| Glibenclamide-CGRP | None | ||||
| Placebo-CGRP | 140 min (20 min) | bilat/3/press/− | − / − /− | no | None |
| 11 | |||||
| Glibenclamide-CGRP | None | ||||
| Placebo-CGRP | None | ||||
| 12 | |||||
| Glibenclamide-CGRP | 130 min (120 min) | bilat/1/press+throb/+ | +/ + /+ | Yes | None |
| Placebo-CGRP | 130 min (120 min) | bilat/1/press+throb/+ | +/ + /+ | Yes | None |
| 13 | |||||
| Glibenclamide-CGRP | 140 min (170 min) | bilat/5/press+throb/− | −/ + /+ | Yes | None |
| Placebo-CGRP | 160 min (70 min) | bilat/6/press+throb/− | +/ + /− | Yes | None |
| 14 | |||||
| Glibenclamide-CGRP | 150 min (140 min) | bilat/3/press+throb/+ | −/ − /− | no | None |
| Placebo-CGRP | 140 min (100 min) | bilat/4/press+throb/+ | −/ + /− | no | None |
| 15 | |||||
| Glibenclamide-CGRP | 130 min (30 min) | bilat/1/press/+ | −/ − /− | no | None |
| Placebo-CGRP | 130 min (30 min) | bilat/1/press/− | −/ − /− | no | None |
| 16 | |||||
| Glibenclamide-CGRP | 540 min (440 min) | bilat/8/press/− | +/ − /+ | no | None |
| Placebo-CGRP | 150 min (450 min) | bilat/2/press/+ | +/ + /− | no | None |
| 17 | |||||
| Glibenclamide-CGRP | 240 min (430 min) | bilat/2/press+throb/− | −/ − /− | no | None |
| Placebo-CGRP | 140 min (20 min) | bilat/1/throb/− | +/ − /− | no | None |
| 18 | |||||
| Glibenclamide-CGRP | none | ||||
| Placebo-CGRP | 160 min (410 min) | bilat/2/press+throb/+ | − / − /− | no | None |
| 19 | |||||
| Glibenclamide-CGRP | 150 min (90 min) | bilat/1/throb/− | + / − /+ | no | None |
| Placebo-CGRP | 130 min (610 min) | bilat/1/press+throb /+ | − / − /− | no | None |
| 20 | |||||
| Glibenclamide-CGRP | 540 min (180 min) | bilat/1/press /− | +/ − /− | no | None |
| Placebo-CGRP | 130 min (70 min) | diffus/1/throb /+ | −/ − /− | no | None |